Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

78.27 +1.13 (+1.46%)
Official Closing Price Updated: 4:10 PM EDT, Jun 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
85 86 Next >
Unpacking the Latest Options Trading Trends in Merck & Co
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
1 Value Stock to Target This Week and 2 to Question
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover
The deal is being discussed ahead of key data from MoonLake in patients with a skin disease. 
Via Investor's Business Daily
Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report
Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
How Do Investors Really Feel About Merck & Co?
Via Benzinga
Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers
Merck shared safety and efficacy results of MK-1084; either as monotherapy or in combinations, it demonstrated a manageable safety profile. 
Via Benzinga
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure
There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival. 
Via Investor's Business Daily
2 Cash-Producing Stocks for Long-Term Investors and 1 to Steer Clear Of
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Merck, Daiichi Sankyo Pull FDA Application For Lung Cancer Therapy: Retail Terms It A ‘Huge Flop’
The decision is based on results from a late-stage trial in which the drug failed to prolong patients' lives, the companies stated. 
Via Stocktwits
Exposures Product Safety
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Reliable Dividend Stock with Strong Fundamentals
MERCK & CO. (NYSE:MRK) offers a strong 4.2% dividend yield, consistent growth, and solid financial health, making it a top pick for dividend investors. 
Via Chartmill
"If Walmart Is Under Pressure to Raise Prices, It's Going to Have Broader Effects on the Economy."
Via The Motley Fool
Topics Earnings Economy World Trade
Exposures Economy Financial Tariff
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge. 
Via Investor's Business Daily
3 Dow Jones Stocks on Our Watchlist
The Dow Jones (^DJI) includes some of the most reliable stocks in the market, and while not all are equal, a few continue to shine. These companies are leveraging their strengths to maintain leadership... 
Via StockStory
Topics Stocks
Exposures US Equities
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Moderna Stock Looks Ripe for a Short Squeeze
Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze 
Via MarketBeat
Topics Government
Exposures COVID-19 Political
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Topics Economy Law Enforcement
Exposures Economy Legal Product Safety
Spotlight on Merck & Co: Analyzing the Surge in Options Activity
Via Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Candidate in Pharmaceuticals
MERCK & CO. (NYSE:MRK) offers strong value with a low P/E ratio, high profitability, and a reliable dividend. A solid pick for value investors in the pharmaceutical sector. 
Via Chartmill
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Decoding Merck & Co's Options Activity: What's the Big Picture?
Via Benzinga
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors. 
Via Benzinga
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo
Immutep's efti combo with Keytruda and chemo shows a 60.8% response rate in lung cancer trial, with strong efficacy across PD-L1 expression levels. 
Via Benzinga
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity. 
Via Benzinga
CMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Up
CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26. 
Via Benzinga
FDA Approves Merck's Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors
Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase. 
Via Benzinga
Exposures Product Safety
3 Absurdly Cheap Stocks Trading Near Their 52-Week Lows
Via The Motley Fool
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?
Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April. 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
85 86 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.